We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Clinical Center of Serbia Treats First Patient in Trial of Stem Cell-Derived Therapy for Heart Failure
News

Clinical Center of Serbia Treats First Patient in Trial of Stem Cell-Derived Therapy for Heart Failure

Clinical Center of Serbia Treats First Patient in Trial of Stem Cell-Derived Therapy for Heart Failure
News

Clinical Center of Serbia Treats First Patient in Trial of Stem Cell-Derived Therapy for Heart Failure

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clinical Center of Serbia Treats First Patient in Trial of Stem Cell-Derived Therapy for Heart Failure"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Clinical Center of Serbia, Institute for Cardiovascular Diseases has announced that it has treated its first patient with a revolutionary cell-based therapy for heart failure. The patient is participating in an international trial of C-Cure®, a second generation cell therapy developed by Cardio3 BioSciences.

C-Cure is produced by taking a patient’s own bone marrow cells and, through a proprietary process, differentiating them into ‘cardiopoietic’ cells that can regenerate damaged heart muscle. The ‘cardiopoietic’ cells are injected into the heart of a patient with heart failure where they are designed to behave identically to those cells lost in heart failure without carrying the risk of rejection, something that has not been achieved with previous cell therapies for this indication.

The trial, a randomized, prospective, multi-center trial, is designed to evaluate the safety and efficacy of C-Cure beyond optimal clinical care in patients with heart failure. Patients will be randomized to C-Cure in addition to optimal standard therapy versus optimal standard therapy alone. The trial will also evaluate socio-economic implications of therapy. The trial is being carried out at various sites in the European Union, and now Serbia.

Dr. Jozef Bartunek, Co-Principal Investigator for the trial commented: “C-Cure is a major breakthrough in the field of cardiac regenerative medicine. This clinical trial will be the very first to apply autologous, guided cardiac progenitor cells. This next generation stem cell product could contribute to the physical and functional regeneration of cells in the chronically infarcted heart”.

Pr. Miodrag Ostojic, Principal Investigator for the trial in the Clinical Center of Serbia, Institute for Cardiovascular Diseases said: “Heart failure is one of the greatest causes of premature death in the world and we are very pleased to be participating in the trial of a product that could potentially transform the treatment of the condition and the outcome for patients.”
Advertisement